Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.190
-0.330-3.47%
Volume:135.37M
Turnover:1.24B
Market Cap:105.89B
PE:27.05
High:9.510
Open:9.510
Low:9.015
Close:9.520
52wk High:11.203
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:1.02
T/O Rate:1.17%
Dividend:0.30
Dividend Rate:3.31%
EPS(LYR):0.340
ROE:20.90%
ROA:10.70%
PB:2.41
PE(LYR):27.05
PS:2.90

Loading ...

CSPC Pharma's New Drug Application for Envituzumab Injection Accepted by Chinese Regulator

Stock News
·
Jul 17

CSPC Pharmaceutical - Nmpa Accepts New Drug Application for Trastuzumab Envedotin Injection

THOMSON REUTERS
·
Jul 17

CSPC Pharmaceutical - Product Indicated for Unresectable or Metastatic Her2-positive Breast Cancer in Adults

THOMSON REUTERS
·
Jul 17

Movement Alert|CSPC Pharmaceutical Falls 3.02% in Regular Trading, Trading at HKD 8.22

Market Focus
·
Jul 17

CSPC Pharma Begins Two Drug Trials in China

MT Newswires Live
·
Jul 16

CSPC PHARMA Initiates Phase II Trial in China for Novel Sirolimus Formulation in Rare Vascular Tumor

Stock News
·
Jul 16

CSPC PHARMA's Phase III Trial for SYS 6043 in Platinum-Resistant Gynecologic Cancers Commences at First Chinese Site

Stock News
·
Jul 16

CSPC Pharmaceutical Initiates China Phase II Trial of Albumin-bound Sirolimus Injection for Epithelioid Haemangioendothelioma

Reuters
·
Jul 16

CSPC Pharmaceutical Initiates China Phase III Trial of Sys6043 in Platinum-resistant Ovarian Cancer

Reuters
·
Jul 16

CSPC Pharmaceutical Group Stock Rallies 2.0% in Hong Kong

Dow Jones
·
Jul 16

Movement Alert|CSPC Pharmaceutical Rises 3.08% in Regular Trading, Breast Cancer Drug Combo Granted Breakthrough Designation Amid Institutional Accumulation

Market Focus
·
Jul 16

CSPC Pharmaceutical Group Stock Rises 3.9% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 15

Movement Alert|CSPC Pharmaceutical Rises 3.08% in Regular Trading, Innovative Drug Combo Granted Breakthrough Therapy Designation for HER2-Positive Breast Cancer

Market Focus
·
Jul 15

CSPC Pharma’s Albumin-Bound Docetaxel and Anbenitamab Secure China Breakthrough Therapy Status for First-Line HER2-Positive Breast Cancer

Bulletin Express
·
Jul 14

Mutual Fund Boosts Stake in Pharmaceutical Giant with Multi-Million Dollar Purchase

Stock News
·
Jul 14

CSPC Says China Regulator Grants Breakthrough Therapy Designation for Her2-positive Breast Cancer Combo

Reuters
·
Jul 14

CSPC Pharmaceutical - Docetaxel (albumin-bound) and Anbenitamab Granted Breakthrough Therapy Designation in China

THOMSON REUTERS
·
Jul 14

CSPC Pharmaceutical Group (SEHK:1093) Gains Attention On Pipeline Progress And AstraZeneca Tie Up

Simply Wall St.
·
Jul 14

CSPC Pharma Secures $25 Million R&D Milestone Payment from AstraZeneca Under Strategic Collaboration

Deep News
·
Jul 12

CSPC Secures US$25.00 Million R&D Milestone from AstraZeneca in Long-Acting Peptide Collaboration

Bulletin Express
·
Jul 10